<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Trial</title>
	<atom:link href="http://www.tapanray.in/tag/trial/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Combating Covid Pandemic: When ‘Something Is Better Than Nothing’</title>
		<link>http://www.tapanray.in/combating-covid-pandemic-when-something-is-better-than-nothing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=combating-covid-pandemic-when-something-is-better-than-nothing</link>
		<comments>http://www.tapanray.in/combating-covid-pandemic-when-something-is-better-than-nothing/#comments</comments>
		<pubDate>Mon, 30 Nov 2020 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA['something is better than nothing']]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[better]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[dosing]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Moderna]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[nothing]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Phase III]]></category>
		<category><![CDATA[Prime Minister]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[side-effects]]></category>
		<category><![CDATA[something]]></category>
		<category><![CDATA[Sputnik V]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[testing]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[useless]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10346</guid>
		<description><![CDATA[As the new Coronavirus overwhelms the world, since its global outbreak, up until November 29, 2020, over 1,458,305 people have died from this pandemic. Understandably, the Governments in all countries are frantically searching for some robust remedial measures to prevent these unfortunate deaths, besides protecting &#8230; <a href="http://www.tapanray.in/combating-covid-pandemic-when-something-is-better-than-nothing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/combating-covid-pandemic-when-something-is-better-than-nothing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Blockchain: Pharma Keeps An Eye On The Ball</title>
		<link>http://www.tapanray.in/blockchain-pharma-keeps-an-eye-on-the-ball/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=blockchain-pharma-keeps-an-eye-on-the-ball</link>
		<comments>http://www.tapanray.in/blockchain-pharma-keeps-an-eye-on-the-ball/#comments</comments>
		<pubDate>Sun, 21 Jan 2018 23:31:36 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bitcoin]]></category>
		<category><![CDATA[Blockchain]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Maharashtra]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Officer]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[SCM]]></category>
		<category><![CDATA[substandard]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[trace]]></category>
		<category><![CDATA[Track]]></category>
		<category><![CDATA[Trial]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8772</guid>
		<description><![CDATA[On April 24, 2017, The Wall Street Journal (WSJ) came out with an interesting headline, “Dubai Aims to Be a City Built on Blockchain.” Some may have taken note of it seriously. However, a vast majority of its readers possibly &#8230; <a href="http://www.tapanray.in/blockchain-pharma-keeps-an-eye-on-the-ball/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/blockchain-pharma-keeps-an-eye-on-the-ball/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Clinical Trials: Critical Need To Improve Patient Participation With Informed Consent</title>
		<link>http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent</link>
		<comments>http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/#comments</comments>
		<pubDate>Mon, 18 Apr 2016 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[alkem]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[consent]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[II]]></category>
		<category><![CDATA[III]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[informed]]></category>
		<category><![CDATA[IV]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[naive]]></category>
		<category><![CDATA[participation]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[phase I]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[Trial]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7600</guid>
		<description><![CDATA[On April 13, 2016, an article in the Wall Street Journal (WSJ) titled, “Clinical Trials Need More Subjects” underscored an important point that the rate at which the clinical researchers are able to recruit and retain patients for ‘Clinical Trials &#8230; <a href="http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Curious Conundrum of New Drugs Approval Process</title>
		<link>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-curious-conundrum-of-new-drugs-approval-process</link>
		<comments>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/#comments</comments>
		<pubDate>Mon, 18 Jan 2016 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Alatrofloxacin]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Aprotinin]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[CDC]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Cochrane]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[curious]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[Drotrecogin alfa]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Economist]]></category>
		<category><![CDATA[EFPIA]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[full]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[International]]></category>
		<category><![CDATA[London]]></category>
		<category><![CDATA[Lumiracoxib]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Matthew Herder]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Propoxyphene]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[registry]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Rofecoxib]]></category>
		<category><![CDATA[Rosiglitazone]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Sibutramine]]></category>
		<category><![CDATA[Tamiflu]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tegaserod]]></category>
		<category><![CDATA[Tetrazepam]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Vioxx]]></category>
		<category><![CDATA[W.H.O]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7360</guid>
		<description><![CDATA[Fathoming the details of just a short span of time, not going beyond the last 10 years, I find from the published data that many new drugs, such as, Alatrofloxacin, Aprotinin, Drotrecogin alfa, Lumiracoxib, Propoxyphene, Rofecoxib, Rosiglitazone, Sibutramine, Tegaserod, Tetrazepam, were &#8230; <a href="http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Repurposing’ Older Drugs: Has The Process Started Rolling?</title>
		<link>http://www.tapanray.in/repurposing-older-drugs-has-the-process-started-rolling/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=repurposing-older-drugs-has-the-process-started-rolling</link>
		<comments>http://www.tapanray.in/repurposing-older-drugs-has-the-process-started-rolling/#comments</comments>
		<pubDate>Mon, 26 Oct 2015 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Aspirin]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[ibuprofen]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[indication]]></category>
		<category><![CDATA[NCATS]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[NIHR]]></category>
		<category><![CDATA[older]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[repurposing]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[statin]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[usage]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7211</guid>
		<description><![CDATA[On October 22, 2015, BBC News reported, “The world&#8217;s largest clinical trial to examine whether aspirin can prevent cancers returning has begun in the United Kingdom (UK).” About 11,000 people, who have had early bowel, breast, prostate, stomach and esophageal cancer &#8230; <a href="http://www.tapanray.in/repurposing-older-drugs-has-the-process-started-rolling/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/repurposing-older-drugs-has-the-process-started-rolling/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Data Manipulation: Leapfrogging Dangerously Into Clinical Trial Domain</title>
		<link>http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain</link>
		<comments>http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/#comments</comments>
		<pubDate>Mon, 03 Aug 2015 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[700]]></category>
		<category><![CDATA[Aurobindo]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[emcure]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[GCP]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[GVK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Jugaad]]></category>
		<category><![CDATA[Leapfrog]]></category>
		<category><![CDATA[Leapfrogging]]></category>
		<category><![CDATA[lifesciences]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[Malpractice]]></category>
		<category><![CDATA[manipulation]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[pharmexcil]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[quest]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rigmarole]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6908</guid>
		<description><![CDATA[Over the last several years, repeated allegations of gross data manipulative practices, detected by global drug regulatory agencies, such as USFDA and MHRA, have shaken the Indian pharma exporting companies hard. This has been hurting the overall business performance of &#8230; <a href="http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Outlook 2015: A Glimpse Of Some Drivers and Barriers</title>
		<link>http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers</link>
		<comments>http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/#comments</comments>
		<pubDate>Mon, 05 Jan 2015 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[exports]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Nadda]]></category>
		<category><![CDATA[outlook]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6291</guid>
		<description><![CDATA[Looking ahead, the brand new year 2015 appears quite interesting to me both from the global and also from the local pharmaceutical industry perspective. In this article I shall try to give a glimpse of some of the important drivers &#8230; <a href="http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Make Global Pharma Responsible in Homeland for Objectionable Conduct in Clinical Trials Elsewhere”</title>
		<link>http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere</link>
		<comments>http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/#comments</comments>
		<pubDate>Wed, 12 Feb 2014 01:30:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Azad]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Chaudhury]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Conduct]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Desiraju]]></category>
		<category><![CDATA[experts]]></category>
		<category><![CDATA[Ghulam]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ISCR]]></category>
		<category><![CDATA[keshav]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Nabi]]></category>
		<category><![CDATA[NGO]]></category>
		<category><![CDATA[objectionable]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Ranjit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roy]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4988</guid>
		<description><![CDATA[In the context of his recent meeting with Commissioner Margaret A. Hamburg of US-FDA, the Drug Controller General of India (DCGI) reportedly expressed his concern to ‘The Economic Times’ on the ‘objectionable conduct’ of global pharma in new drug trials &#8230; <a href="http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Clinical Trial Regime Deserves Support, Sans Threats</title>
		<link>http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-clinical-trial-regime-deserves-support-sans-threats</link>
		<comments>http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/#comments</comments>
		<pubDate>Thu, 30 Jan 2014 11:19:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[59th]]></category>
		<category><![CDATA[CAC]]></category>
		<category><![CDATA[catalytic]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Chaudhury]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NGO]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Ranjit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regime]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Roy]]></category>
		<category><![CDATA[sans]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[threats]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4943</guid>
		<description><![CDATA[Recent Supreme Court intervention compelling the Union Government to enforce stringent regulations both for approval and conduct of Clinical Trials (CT) in India, has unfortunately met with some strong resistance with stronger words. Some of these voices are from credible &#8230; <a href="http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sets 2013, Dawns 2014: Top 7 Pharma Developments</title>
		<link>http://www.tapanray.in/sets-2013-dawns-2014-top-7-pharma-developments/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=sets-2013-dawns-2014-top-7-pharma-developments</link>
		<comments>http://www.tapanray.in/sets-2013-dawns-2014-top-7-pharma-developments/#comments</comments>
		<pubDate>Mon, 30 Dec 2013 23:20:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[back]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Crystal]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[Gazing]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[heralds]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Looking]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recounts]]></category>
		<category><![CDATA[revoke]]></category>
		<category><![CDATA[salient]]></category>
		<category><![CDATA[sets]]></category>
		<category><![CDATA[Seven]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4721</guid>
		<description><![CDATA[Wish You Good Health, Happiness, Success and Prosperity in 2014 In this article I shall focus on &#8216;Top 7 Pharma Developments’, both while ‘Looking Back to 2013&#8242; and also during my ‘Crystal Gazing 2014&#8242;. Looking Back to 2013: While looking &#8230; <a href="http://www.tapanray.in/sets-2013-dawns-2014-top-7-pharma-developments/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/sets-2013-dawns-2014-top-7-pharma-developments/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
